1001/jamainternmed
9 and 62
During the follow-up period, there was a significant reduction in the incidence of ischemic
001); discontinuation was The incidence of ischemic cardiovascular events (the primary efficacy outcome) was lower in the ticagrelor group than in the placebo group (7
5% ST-elevation MI), 1,035 were discharged on ticagrelor and clopidogrel, respectively
All-cause mortality, MACEs, MI, stroke, and stent thrombosis were not significantly different with clopidogrel versus with (OR: 0
4%) received ticagrelor plus aspirin and 957 received clopidogrel plus aspirin
by Drugs
Park et al
Objectives Evidence of the optimal antiplatelet therapy for elderly patients who had a stroke is limited, especially those elder than 80 years
4% (adjusted hazard ratio (HR) 0
Clopidogrel or Ticagrelor in Acute Coronary Syndrome Patients Treated With Newer-Generation Drug-Eluting Stents: CHANGE DAPT
In patients with acute coronary syndrome (ACS), dual antiplatelet therapy (DAPT) has been the cornerstone strategy
The highest doses of ticagrelor (100 mg and 200 mg twice/day, and 400 mg/day) achieved peak IPA within
11%, respectively) treatment was similar in the clopidogrel and ticagrelor group at 1 year
103,104 In the
Therapeutics Letter 94 analyses published RCTs comparing these two new platelet inhibitors with clopidogrel, and includes additional information available from the US FDA’s medical reviews of these RCTs
94; 95% CrI, 0
We aimed to compare the effect of ticagrelor vs
9%)
84))
99; Figure 4A); similarly, ticagrelor was nominally more effective than clopidogrel in reducing all-cause mortality for all age categories calculated using 5-year categorical age ranges
clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
001); discontinuation was Brilinta has an average rating of 3
Mechanism of Action: Reversibly binds to the P2Y 12 class of adenosine diphosphate (ADP) receptors on platelets to prevent signal The rates of fatal bleeding (0
79, 2452–2460 (2015)
Ticagrelor use in patients ≥80 years of age is associated with excess risk of death and bleeding compared to clopidogrel